USA - NASDAQ:ATAI - NL0015000DX5 - Common Stock
The current stock price of ATAI is 4.592 USD. In the past month the price decreased by -14.51%. In the past year, price increased by 209.22%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.61 | 928.54B | ||
| JNJ | JOHNSON & JOHNSON | 18.02 | 450.41B | ||
| MRK | MERCK & CO. INC. | 9.83 | 216.22B | ||
| PFE | PFIZER INC | 7.69 | 139.88B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.17 | 95.73B | ||
| ZTS | ZOETIS INC | 19 | 53.39B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.52 | 22.83B | ||
| VTRS | VIATRIS INC | 4.33 | 11.77B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.24 | 11.09B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.54 | 7.75B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.11 | 4.02B |
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
ATAI BECKLEY NV
Prof. J.H.Bavincklaan 7
Amstelveen NOORD-HOLLAND 100022 NL
CEO: Florian Brand
Employees: 54
Phone: 31207932536
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
The current stock price of ATAI is 4.592 USD. The price increased by 5.32% in the last trading session.
ATAI does not pay a dividend.
ATAI has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
17 analysts have analysed ATAI and the average price target is 12.35 USD. This implies a price increase of 169.02% is expected in the next year compared to the current price of 4.592.
ATAI BECKLEY NV (ATAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).
The Revenue of ATAI BECKLEY NV (ATAI) is expected to grow by 355.42% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ChartMill assigns a technical rating of 5 / 10 to ATAI. When comparing the yearly performance of all stocks, ATAI is one of the better performing stocks in the market, outperforming 97.13% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to ATAI. While ATAI has a great health rating, there are worries on its profitability.
Over the last trailing twelve months ATAI reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS decreased by -72.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.89% | ||
| ROE | -103.85% | ||
| Debt/Equity | 0 |
17 analysts have analysed ATAI and the average price target is 12.35 USD. This implies a price increase of 169.02% is expected in the next year compared to the current price of 4.592.
For the next year, analysts expect an EPS growth of 45.22% and a revenue growth 355.42% for ATAI